Psoriatic Arthritis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 151 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Psoriatic Arthritis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H2 2014', provides an overview of the Psoriatic Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Psoriatic Arthritis Overview 10
Therapeutics Development 11
Pipeline Products for Psoriatic Arthritis - Overview 11
Pipeline Products for Psoriatic Arthritis - Comparative Analysis 12
Psoriatic Arthritis - Therapeutics under Development by Companies 13
Psoriatic Arthritis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Psoriatic Arthritis - Products under Development by Companies 19
Psoriatic Arthritis - Companies Involved in Therapeutics Development 20
Bristol-Myers Squibb Company 20
Amgen Inc. 21
Eli Lilly and Company 22
Celltrion, Inc. 23
Novartis AG 24
Biocon Limited 25
Pfizer Inc. 26
UCB S.A. 27
Sandoz Inc. 28
Celgene Corporation 29
Swedish Orphan Biovitrum AB 30
Panacea Biotec Limited 31
Alder Biopharmaceuticals Inc. 32
Coronado Biosciences, Inc. 33
Kineta, Inc. 34
Avesthagen Limited 35
Covagen AG 36
Forward Pharma A/S 37
Inbiopro Solutions Pvt. Ltd. 38
Innovent Biologics, Inc. 39
Epirus Biopharmaceuticals, Inc. 40
AlphaMab Co., Ltd 41
Psoriatic Arthritis - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
apremilast - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
secukinumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
brodalumab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ixekizumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
tofacitinib - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
abatacept - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
infliximab biosimilar - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
etanercept biosimilar - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
adalimumab biosimilar - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
clazakizumab - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
infliximab biosimilar - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
COVA-322 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
dimethyl fumarate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ShK-186 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
UCB-4940 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
infliximab biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
adalimumab biosimilar - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
etanercept biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
itolizumab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
CNDO-201 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
etanercept biosimilar - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
adalimumab biosimilar - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
etanercept biosimilar - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
etanercept biosimilar - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
etanercept biosimilar - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
etanercept biosimilar - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
adalimumab biosimilar - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
adalimumab biosimilar - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
adalimumab biosimilar - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
INV-17 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
IBI-303 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
adalimumab biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
anakinra - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
IBPM-005IX - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
IBPM-004AM - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Psoriatic Arthritis - Recent Pipeline Updates 103
Psoriatic Arthritis - Dormant Projects 138
Psoriatic Arthritis - Discontinued Products 139
Psoriatic Arthritis - Product Development Milestones 140
Featured News & Press Releases 140
Sep 25, 2014: Novartis AIN457 (secukinumab) is the first ever IL-17A inhibitor to meet primary endpoint in two Phase III studies in psoriatic arthritis 140
Jul 16, 2014: Celltrion's Remsima receives Turkey Ministry of Health approval 140
Jun 11, 2014: Oral OTEZLA (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Na�ve Patients with Active Psoriatic Arthritis 141
Jun 11, 2014: Oral OTEZLA (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis 142
Jun 11, 2014: Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine 143
Apr 14, 2014: ReCept Pharmacy to Distribute Otezla (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic Arthritis for Adults 145
Apr 10, 2014: Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS (Prednisone) Delayed-Release Tablets 145
Apr 04, 2014: Diplomat to distribute Otezla (apremilast), newly approved medication for psoriatic arthritis 146
Mar 27, 2014: NICE set not to recommend ustekinumab for psoriatic arthritis 146
Mar 21, 2014: OTEZLA - First Oral Therapy Approved by the U.S. Food and Drug Administration for the Treatment of Adults with Active Psoriatic Arthritis 147
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Tables
Number of Products under Development for Psoriatic Arthritis, H2 2014 11
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2014 20
Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2014 21
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2014 22
Psoriatic Arthritis - Pipeline by Celltrion, Inc., H2 2014 23
Psoriatic Arthritis - Pipeline by Novartis AG, H2 2014 24
Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2014 25
Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2014 26
Psoriatic Arthritis - Pipeline by UCB S.A., H2 2014 27
Psoriatic Arthritis - Pipeline by Sandoz Inc., H2 2014 28
Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2014 29
Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H2 2014 30
Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H2 2014 31
Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 32
Psoriatic Arthritis - Pipeline by Coronado Biosciences, Inc., H2 2014 33
Psoriatic Arthritis - Pipeline by Kineta, Inc., H2 2014 34
Psoriatic Arthritis - Pipeline by Avesthagen Limited, H2 2014 35
Psoriatic Arthritis - Pipeline by Covagen AG, H2 2014 36
Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2014 37
Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 38
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2014 39
Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 40
Psoriatic Arthritis - Pipeline by AlphaMab Co., Ltd, H2 2014 41
Assessment by Monotherapy Products, H2 2014 42
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 48
Number of Products by Stage and Route of Administration, H2 2014 50
Number of Products by Stage and Molecule Type, H2 2014 52
Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H2 2014 103
Psoriatic Arthritis - Dormant Projects, H2 2014 138
Psoriatic Arthritis - Discontinued Products, H2 2014 139